Grants for Native American Tribal Organizations

This funding opportunity supports high-risk, multi-center clinical trials aimed at addressing significant health issues related to diabetes, digestive diseases, and kidney disorders, encouraging diverse institutions to apply for impactful research that can transform clinical practices.

This funding opportunity supports researchers in planning high-risk, multi-center clinical studies focused on kidney, digestive, diabetes, and metabolic disorders, helping them develop essential protocols and administrative frameworks before conducting the actual trials.

This funding opportunity supports institutions in developing clinician scientists through structured research training in substance use and addiction, enabling them to pursue independent research careers.

This grant provides funding for innovative research and development projects in coastal, hydraulic, geotechnical, environmental, and cold regions engineering, aimed at enhancing national security and infrastructure resilience.

The Tarrant Foundation awards between 50 – 70 competitive grants annually. Because we believe we can have the most impact by concentrating these funds in Vermont, applications are accepted only from Vermont organizations. Seniors: Comfort and Dignity in Aging We believe in ensuring that seniors’ most basic needs are met, and in community-based supports that promote wellbeing and fight the premature limitation of independence. Our focus includes: independent living, nutrition, and activity & enrichment.

This program provides financial assistance to rural communities in Idaho for infrastructure projects that promote economic development and job creation.

This program provides funding to Alaska Native entities for the assessment and cleanup of contaminated lands conveyed under the Alaska Native Claims Settlement Act, addressing environmental injustices and promoting community health and well-being.

This grant provides financial support to Vermont-based nonprofits focused on youth development, economic independence for working adults, senior care, and community enhancement initiatives.

The Tarrant Foundation awards between 50 – 70 competitive grants annually. Because we believe we can have the most impact by concentrating these funds in Vermont, applications are accepted only from Vermont organizations. Working-Age Adults: Employment and Financial Independence We support strategies that promote and facilitate the journey to economic independence, and that ultimately reduce reliance on public assistance. Our focus includes: job training/retention, financial literacy, homelessness prevention, and community-based addiction recovery.

This funding opportunity supports researchers and institutions conducting clinical trials and studies to improve stroke treatment, recovery, and prevention through collaboration within a national network.

This funding opportunity supports early stage researchers in pursuing innovative and high-risk scientific projects that significantly diverge from their previous work, without the need for preliminary data.

The Office of Child Support Services (OCSS) forecast provides information for eligible candidates interested in submitting applications for the Next Generation Child Support Employment Services Demonstration (NextGen). The NextGen program model is based on lessons learned from the National Child Support Noncustodial Parent Employment Demonstration. Its goal is to expand and enhance child support-led employment services for noncustodial parents. All state and tribal child support programs are eligible. Each applicant will self-identify into one of the following three mutually exclusive groups:Tribal child support agenciesState child support agencies where at least one local jurisdiction participating in the demonstration does not currently have an employment and training program or the program has been in operation for less than 5 yearsState child support agencies where all local jurisdictions participating in the demonstration have had an employment and training program in operation for at least 5 yearsAll groups are expected to implement their employment and training programs according to the program design elements described below. Deviations are allowed, but they must be justified, and the applicant must explain how they propose to handle the design elements described below.All groups are expected to provide the following child support and related services to noncustodial parents who receive employment and training services:Initiating and expediting order review and if appropriate modificationSuspending enforcement tools while participating in the program, including removing license suspensions and bench warrantsProviding debt reduction if permitted by state lawHelping with parenting time ordersWraparound services, such as fatherhood and parenting classes, substance abuse, or mental health services, are a plus but not required. OCSS anticipates that the grant recipient will partner with other agencies and programs to provide the employment and training services and other wraparound services.Experience shows that programs work best if each partner focuses on their core competencies. The child support program is expected to be the fiscal agent, manage the day-to-day operation of the program, and provide child support and related services, including those listed above. OCSS does not anticipate that child support staff will provide the employment and training services or wraparound services since these are not the child support program core competencies. These services may be paid for by the grant, but in most instances, they will be delivered by partnering agencies.This grant program will have a 60-month project period with five 12-month budget periods. Year 1 will focus on start-up and development of the program design. Years 2, 3, and 4 will be devoted to providing services, and the final year will be dedicated to evaluation, close-out, and sustainability work. Grant recipients will receive technical assistance and evaluation support from the recipient of the Technical Assistance and Evaluation of the Next Generation Child Support Employment Services Demonstration grant (see companion forecast). They will also participate in peer-to-peer learning opportunities.Recipients may receive between $350,000 and $2,102,941 over the 5-year project period. The award ceilings and floors for each project year is as follows:Year 1 (initial application): $588,235 ceiling and $100,000 floorYear 2: $588,235 ceiling and $100,000 floorYear 3: $308,824 ceiling and $50,000 floorYear 4: $308,824 ceiling and $50,000 floorYear 5: $308,824 ceiling and $50,000 floorOCSS anticipates that the budget requested will be scaled up or down according to the number of people served by the project.

The Office of Child Support Services (OCSS) forecast provides information for eligible candidates interested in submitting applications for the Technical Assistance and Evaluation of the Next Generation Child Support Employment Services Demonstration (NextGen TA/Eval). This will be a cooperative agreement awarded to a single state or tribal child support agency. Under this cooperative agreement, the selected recipient will procure and manage an independent third-party organization(s) to provide technical assistance and evaluate the demonstration projects funded under the forecasted companion Notice of Funding Opportunity (NOFO) HHS-2024-ACF-OCSE-FD-0015, Next Generation Child Support Employment Services Demonstration. This cooperative agreement will have a 60-month project period with five 12-month budget periods. Required activities will include:Implementation tracking and evaluationOutcome tracking and evaluationProviding programmatic and evaluation technical assistance to demonstration grant recipients, including leading regularly scheduled virtual learning community webinars and annual in-person meetings throughout the 5-year project periodImplementing and overseeing a Management Information System for grant recipients under the companion NOFO that systematically collects program services and short-term outcomes for participants in the demonstration projects funded under the companion NOFO or developing some other method to collect this informationDisseminating technical assistance materials, completed evaluation reports, and other lessons learned to a national audience, including presenting at national or state conferences. This may include offering technical assistance and support to non-grant recipient child support programs who want to start and/or strengthen their own child support-led employment services programs.Applicants for this grant may also apply under the companion NOFO, but it is not a requirement for application or selection under this announcement. A successful applicant under this NOFO may also be selected as a successful applicant under the companion NOFO, but one award is not related to the other. The recipient of this award will select a third-party organization to conduct the evaluation and will maintain impartiality regarding the evaluation of all project sites.OCSS forecasts the awardee may receive up to $8,057,059 over the 5-year project period. The annual award ceiling for years 1-2 is $3,587,353. The annual award ceiling for years 3-5 is $294,118. The award floor is the same as the ceiling and average cost.

The National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for the TrialNet Clinical Network Hub (HUB). The purpose of this Notice of Funding Opportunity (NOFO) is to continue support for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), a screening and clinical activities coordination unit for clinical trials focusing on the prevention of and early intervention in type 1 diabetes (T1D). The main objective of the HUB is to increase the efficiency and productivity of the TrialNet network by providing coordination of communications and outreach and developing new tools and approaches to increase screening, recruitment and retention. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Spring 2024 with an expected application due date in Summer 2024. This NOFO will utilize the U01 activity code. Details of the planned NOFO are provided below.

The National Cancer Institute (NCI) intends to issue the U54 Specialized Programs of Research Excellence in Cancer Health Disparities and Minority Health (CHD-MH SPORE) notice of funding opportunity (NOFO). The program will support a network of multidisciplinary, multi-institutional U54 CHD-MH SPOREs, which are multi-project awards uniquely focused on health disparities and/or minority health translational research for improved prevention, early detection, diagnosis, and treatment of cancer in populations who are underserved. U54 CHD-MH SPOREs can investigate more than one cancer type in underserved populations, including groups of highly related cancers (e.g., gastrointestinal or head and neck). The research supported through this program must be translational and must stem from research on human biology, addressing the interplay of various determinants of health with the biology of the disease. U54 CHD-MH SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant, which may include a clinical trial. This Notice of Intent to Publish is being provided to allow sufficient time for applicants to develop strong applications. The NOFO is expected to be published in late winter 2024 with only one expected application due date in late September 2024.

The National Institute on Aging (NIA), part of the National Institutes of Health (NIH), intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose to establish a national Open Measurement Coordinating Network for Non-Pharmacological Alzheimer's Disease (AD) and AD-related Dementias (ADRD) Primary Prevention Trials. The Network will serve as a centralized hub for developing, validating, standardizing, and disseminating measures and measurement methods for AD/ADRD primary prevention trials. It will incorporate measures and measurement methods across neuropsychological, biomarker, and functional domains to meet the goal of primary prevention of AD/ADRD centered around brain health equity. Brain health equity is the fair distribution of brain health determinants, outcomes, and resources within and between segments of the population, regardless of social standing. Measures and methods of interest will test outcomes and mechanisms of action in settings customized for individuals with different needs and linked to real-world function. Applications must explain how the platform will meet evolving community needs and partner with other NIA-funded programs. Applications must also describe activities that will achieve the following objectives: Develop an organizational and governance structure to support the administration, innovation, and dissemination functions of the Network. Propose activities to establish a framework that will facilitate the development of innovative strategies for standardization and use of methods and measures across NIA-supported projects and support activities for the discovery and development of innovative and novel measures and data. Disseminate Network resources and products to the broader AD/ADRD research community. Ensure that all measures and methods development and validation occurs in a racially, ethnically, geographically, and diagnostically diverse set of participants, including members of NIH-defined Health Disparity Populations. This also includes establishing the acceptability and feasibility of using the proposed instruments in both cognitively normal individuals and persons living with cognitive impairment (PLWCI), including subjective cognitive decline. NIA is particularly interested in proposals that advance equity for populations disproportionately impacted by AD/ADRD. For example, Black and Hispanic Americans have a higher prevalence of AD/ADRD compared to non-Hispanic White Americans. Resources, including measurement instruments, methods, algorithms, code, documentation, and normative data will enable other, future measures and methods development projects that support AD/ADRD primary prevention research needs. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in early 2024 with an expected application due date in Spring/Summer 2024. This NOFO will utilize the U24 activity code.

The National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for the TrialNet Coordinating Center (TNCC). The TrialNet network identifies people with type 1 diabetes (T1D) at stages before and after onset of clinical symptoms and enrolls them in trials and studies aimed at prevention of progression to clinical disease and preservation of insulin production. The TNCC participates in ongoing studies and intervention trials as well as the design and conduct of new studies and intervention trials. The TNCC will: (1) support a wide range of research projects in varying stages of development, implementation and completion, and (2) provide data and sample management, including standardized acquisition, quality control, dissemination and public accessibility. The TNCC will be responsible for network administration and operations, including the evaluation, selection, and funding (through subcontracts) of Clinical Centers and central support units (such as laboratories) necessary for the conduct of TrialNets clinical studies. The TNCC PD/PI will be a voting member of the TrialNet Executive and Steering Committees, contributing to network leadership. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Spring 2024 with an expected application due date in Summer 2024. This NOFO will utilize the U01 activity code. Details of the planned NOFO are provided below.

This grant provides funding for early stage investigators to pursue innovative and high-risk research projects involving human participants, without the need for preliminary data.

Allergic reactions to drugs and vaccines are a serious public health concern. For the purpose of this notice of funding opportunity (NOFO), allergic reactions include not only IgE-mediated reactions, but other immune-mediated and largely unpredictable drug and vaccine reactions. Based on data from 2013-2014, each year in the United States there are an estimated 200,000 emergency department visits for adverse events related to antibiotics. In children 5 or younger, antibiotics cause more than half (56%) of estimated emergency department visits for adverse drug events and 82% of these visits are due to allergic reactions. Allergic reactions to antibiotics include immediate life-threatening reactions such as anaphylaxis, severe cutaneous reactions including Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms, and less severe reactions that still limit further use of the drugs. A label of antibiotic allergy leads to the use of alternative, frequently more expensive antibiotics, often with lower efficacy, which may contribute to antibiotic resistance as well as increased mortality and morbidity in hospitalized patients. While allergic reactions to vaccines are less common, the inability to receive a vaccine due to an allergy is problematic to the individual, and the perceived risk of allergic reactions to vaccines contributes to vaccine hesitancy creating a public health issue. Objectives The objective of this NOFO is to solicit innovative projects to study the mechanisms and management of vaccine or antibiotic drug allergy (research on allergic responses to anti-viral, anti-fungal and anti-parasitic drugs will also be considered). The scope of research into antibiotic or vaccine allergic reactions includes, but is not limited to, the following: IgE-mediated and other mechanisms of immediate allergic antibiotic or vaccine reactions Non-IgE-mediated urticarial reactions to antibiotics or vaccines Delayed-type hypersensitivity reactions to antibiotics or vaccines Severe cutaneous adverse antibiotic or vaccine reactions Biomarkers to identify people at risk for reaction or to confirm reactions to specific antibiotics or vaccines Host factors that may predispose to allergic reactions including, but not limited to, host microbiome, genetics, or inflammatory conditions Mechanisms by which specific infections may increase the risk of an allergic reaction to an antibiotic or vaccine Immunomodulatory approaches to treating or preventing immunologic adverse antibiotic or vaccine reactions A secondary objective of this NOFO is to expand the number of investigators working in the field of vaccine and antibiotic drug allergy. Early-stage investigators are encouraged to apply. UG3/UH3 phase transition and Milestones This funding opportunity is designed as a two-stage cooperative agreement in which Project Scientists from NIAID will work with the investigative team. It will support projects that are organized into a two-year UG3 phase followed by a three-year UH3 phase. The UG3 phase may include pilot, observational, or hypothesis-generating high-risk projects. Preliminary data may be helpful but are not required. The use of electronic health records to identify potential participants for mechanistic studies is allowed. The use of human samples such as those related to clinically indicated and routinely used interventions or tests is encouraged. The UG3 must include milestones to determine the success of the project at the end of this phase. Milestones may be negotiated or re-negotiated after award as this program includes the flexibility to quickly revise milestones and/or aims within the scope of the original peer-reviewed application. Following the completion of the UG3 phase, NIAID staff will review the progress made and make the determination on whether the project will continue to the UH3 phase. NIAID support for the UH3 is contingent upon progress made during the UG3 phase, meeting the milestones, programmatic priorities, the original UG3/UH3 peer review recommendations, and the availability of funds. Some projects might not transition from the UG3 to the UH3 phase. Projects supported by the UH3 phase are required to be hypothesis driven, mechanistic, and extend the work initiated by the UG3 phase. Program Director/Principal Investigator (PD/PI) Meeting Attendance A kick-off meeting and annual meetings will be organized by NIAID to facilitate interactions among recipients to share approaches, data, and methods, with the aim of developing a cadre of dedicated researchers to conduct antibiotic and vaccine allergy and advance mechanistic research. These meetings will convene yearly in the Rockville, Maryland area and will be held in person, though a virtual component will be available to allow broader participation from laboratory members. The PD/PI from each award is expected to attend the kickoff meeting and annual meetings in person. Applications that propose the following topics will be considered non-responsive and will not be reviewed: Adverse drug reactions that are predictable and/or related to pharmacologic properties of the drug such as toxicity or overdose Investigation into drugs that are not antibiotics or vaccines (however research on anti-viral, anti-fungal and anti-parasitic drugs is allowed) Investigations into Guillain-Barré Syndrome or drug-induced autoimmune reactions Investigations of central nervous system and other neurologic adverse responses Investigations into the pathogens rather than host allergic responses to the antibiotics or vaccines Applications that do not propose mechanistic research in the UH3 phase Vaccines that are administered via a route that is not the same route of administration as approved by the FDA Vaccines that are used as an immunotherapeutic (e.g. allergen immunotherapy) HIV/AIDS research

This funding opportunity supports researchers conducting fully remote clinical trials to evaluate the effectiveness of complementary and integrative health interventions, utilizing mobile health technologies without any in-person contact.